Rua Bioscience Limited (NZX: RUA) formally announced today that it has received its first order via its German distributer Nimbus Health, marking a significant commercial milestone for the export-focused company.
Managing Director, Anna Stove, says “Receiving this order for dried flower from Nimbus signifies just how close we are to cementing export revenues and providing German patients with a sustainable supply of Rua medicines”.
The order is for Rua’s high THC flower, which has been developed through an extensive R&D programme by Cann Group, Rua’s Australian manufacturing, supply and technical services partner. In Germany, medicinal dried-cannabis flower is prescribed mainly for pain patients (70%), and cannabis flowers with a THC content of greater than 20% make up 77% of cannabis flower prescriptions.
“At its launch, we believe Rua’s flower will be one of the highest THC dried flower medicines on the market, which will give Rua a significant competitive advantage,” she says.
